| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
EVP, Wwc. Innovative Medicine | EVP, Ww Chair, Pharmaceuticals
1 company
Taubert Jennifer L serves as an EVP, Wwc. Innovative Medicine at JNJ. Across recent SEC filings that breaks down to 0 buys and 4 sells. Those positions are worth an estimated $51.2M at current prices.
Historically, Taubert Jennifer L's trades have earned a middling insider score of 60/100 across 3 rated trades. Over a 12-month horizon, 100.0% of those trades were profitable, with an average 12-month return of +8.5%.
The biggest single holding is JNJ (~$51.2M) as EVP, Wwc. Innovative Medicine. The recent filings there lean toward selling, a net 207,791 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Aug 17, 2026 | JNJ Johnson & Johnson | EVP, Wwc. Innovative Medicine | Sale+OE | 15,000 | $263.36 | $3,950,400.00 | -7.2% | - | - | |
| Sep 4, 2025 | JNJ Johnson & Johnson | EVP, Wwc. Innovative Medicine | Sale+OE | 56,471 | $177.81 | $10,040,882.63 | -24.1% | +14.9% | +54.0% | |
| Feb 9, 2024 | JNJ Johnson & Johnson | EVP, Ww Chair, Pharmaceuticals | Sale+OE | 59,397 | $156.27 | $9,281,969.19 | -29.6% | -4.4% | -2.3% | |
| Nov 22, 2022 | JNJ Johnson & Johnson | EVP, Ww Chair, Pharmaceuticals | Sale+OE | 76,923 | $176.78 | $13,598,401.79 | -37.8% | -10.6% | -14.7% |